Mirum Pharmaceuticals (NASDAQ:MIRM) COO Peter Radovich Sells 2,382 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 2,382 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total transaction of $222,312.06. Following the completion of the transaction, the chief operating officer directly owned 20,679 shares in the company, valued at $1,929,971.07. This trade represents a 10.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $94.29 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $96.84. The business’s 50-day moving average price is $77.33 and its two-hundred day moving average price is $70.64. The company has a market capitalization of $4.85 billion, a P/E ratio of -109.64 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.15. The business had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm’s revenue was up 47.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.30) EPS. Analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Wall Street Analyst Weigh In

MIRM has been the subject of several analyst reports. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Stifel Nicolaus boosted their price target on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. TD Cowen reissued a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $102.58.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MCF Advisors LLC lifted its holdings in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares during the last quarter. Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals during the third quarter worth $33,000. Quarry LP bought a new position in Mirum Pharmaceuticals during the third quarter worth $41,000. CWM LLC raised its stake in Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the last quarter. Finally, Comerica Bank boosted its holdings in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.